Paradigm Biopharmaceuticals Ltd
PAR
Company Profile
Business description
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
Contact
500 Collins Street
Level 15
MelbourneVIC3000
AUST: +61 396295566
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Will China strong arm BHP into lower iron ore prices?
Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
stocks
Chart of the Week: Where Morningstar sees attractive dividend yields in 26/27
Charts from the Australian Dividend Outlook show the sectors where they are abundant.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,276.60 | 19.90 | -0.21% |
| CAC 40 | 8,041.36 | 18.77 | -0.23% |
| DAX 40 | 24,611.25 | 14.12 | 0.06% |
| Dow JONES (US) | 46,358.42 | 243.36 | -0.52% |
| FTSE 100 | 9,509.40 | 39.47 | -0.41% |
| HKSE | 26,752.59 | 76.87 | -0.29% |
| NASDAQ | 23,024.63 | 18.75 | -0.08% |
| Nikkei 225 | 48,580.44 | 845.45 | 1.77% |
| NZX 50 Index | 13,523.61 | 47.25 | -0.35% |
| S&P 500 | 6,735.11 | 18.61 | -0.28% |
| S&P/ASX 200 | 8,969.80 | 25.20 | -0.28% |
| SSE Composite Index | 3,933.97 | 51.20 | 1.32% |